SNPMiner Trials by Shray Alag


SNPMiner Trials: Mutation Report

Report for Mutation Q141K

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

NCT02956278 Chronic Gout Hyperuricemia Drug: Allopurinol Other: Placebo
MeSH: Hyperuricemia
HPO: Hyperuricemia

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics. --- Q141K ---

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics. --- Q141K ---

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics. --- Q141K --- --- Q141K ---

Primary Outcomes

Measure: Allopurinol/Oxypurinol Renal Clearance

Time: as determined by blood/urine levels taken over the course of one week

Measure: Uric Acid Levels

Time: as determined by blood/urine levels taken over the course of one week

Secondary Outcomes

Measure: Allopurinol/Oxypurinol steady state concentrations

Time: as determined by blood/urine levels taken over the course of one week

Measure: Allopurinol/Oxypurinol AUC

Time: as determined by blood levels taken over the course of one week

HPO Nodes

Hyperuricemia
Genes 24
ALMS1 MYC HNF4A ALDOB ACAT1 MUC1 SEC61A1 UMOD G6PC EIF2AK3 SLC37A4 HNF1B SH2B1 HMGCL HPRT1 REN TNFRSF11B TNFRSF11A SARS2 FBP1 PPARG PFKM CLDN16 PRPS1